Cell-Based Immunotherapies
3D-EXplore can be used to investigate and qualify the penetration, and tumor cell killing capabilities of all cell-based immunotherapies including Tumor Infiltrating Lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, Gamma delta (γδ T-cells ) cell therapy and chimeric antigen receptor T cell (CAR-T) therapy.
WHY ARE CELL-BASED IMMUNOTHERAPIES IMPORTANT?
Adoptive cell therapies (ACTs), also known as cellular or cell-based immunotherapies, are therapeutic interventions that utilize immune cells to target tumor cells. Cytotoxic T cells are particularly powerful against cancer, due to their ability to bind to antigens on the surface of cancer cells. Cell-based immunotherapies take advantage of this natural ability, and with 3D-EXplore we have the unique ability to investigate and quantify the penetration and efficacy of these therapies.
Capabilities
SCIENTIFIC DATA
High content confocal microscopy can be used to quantify tumor-mediated cell killing as shown in this example image. Comparing the number of dead cells following treatment with CAR-T cells in control versus treated tumoroids, as well as quantify the penetration distance of cell tracker CAR-Ts. This demonstrates that the heterogeneity of the tumor microenvironment heavily influences the effectiveness of the therapy with varying levels of penetration and CAR-T-mediated tumor cell killing due to the unique stromal composition of each tumor.
Related Resources
Browse our latest posters and presentations using Nilogen's fresh patient tumoroid technology.
